We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

30 hedge funds and large institutions have $22.4M invested in Protara Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $13.6M → $22.4M (+$8.71M)

0% more funds holding

Funds holding: 30 → 30 (0)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% more ownership

Funds ownership: 1.26% → 1.26% (+0%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
30
Holders Change
–
Holders Change %
0%
% of All Funds
0.69%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
5
Increased
2
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$78.7K
2
BFM
Boothbay Fund Management
New York
+$68.3K
3
Citadel Advisors
Citadel Advisors
Florida
+$41.1K
4
DS
DRW Securities
Illinois
+$34.1K
5
VF
Virtu Financial
New York
+$33.6K

Top Sellers

1
WS
Wedbush Securities
California
-$53K
2
KCM
Kornitzer Capital Management
Kansas
-$21K
3
ACM
Asymmetry Capital Management
California
-$18K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$16.9K
5
UBS Group
UBS Group
Switzerland
-$13.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$5.04M – – –
PI
2
Pharmstandard International
Luxembourg
$4.17M – – –
RCM
3
RA Capital Management
Massachusetts
$3.34M – – –
DM
4
Deerfield Management
New York
$3.06M – – –
MAM
5
MPM Asset Management
Massachusetts
$2.46M – – –
PA
6
Perceptive Advisors
New York
$835K – – –
DVC
7
Deer VII & Co
New York
$788K – – –
BBA
8
Baker Bros. Advisors
New York
$746K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$590K +$78.7K +865 +17%
Vanguard Group
10
Vanguard Group
Pennsylvania
$520K -$5.18K -57 -1%
DS
11
DRW Securities
Illinois
$134K +$34.1K +375 +39%
FCI
12
Financial Counselors Inc
Kansas
$125K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$80K – – –
BFM
14
Boothbay Fund Management
New York
$75K +$68.3K +751 New
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$46K – – –
Citadel Advisors
16
Citadel Advisors
Florida
$45K +$41.1K +452 New
Northern Trust
17
Northern Trust
Illinois
$40K -$455 -5 -1%
PAM
18
Panagora Asset Management
Massachusetts
$39K – – –
VF
19
Virtu Financial
New York
$37K +$33.6K +369 New
ARTA
20
A.R.T. Advisors
New York
$32K -$6.37K -70 -18%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$31K -$16.9K -186 -38%
RJFSA
22
Raymond James Financial Services Advisors
Florida
$31K – – –
Mariner
23
Mariner
Kansas
$25K – – –
LWCFA
24
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$16K – – –
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$13K – – –
1
2

TARA Hedge Fund Activity: Q1 2018 in Review

30 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2018, worth a combined $22.4M — up 64% from $13.6M a quarter earlier.

Fund positioning in TARA was balanced in Q1 2018: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 6 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $78.7K. The largest seller was Wedbush Securities, exiting entirely with an estimated $53K sold.

  • 30 institutional investors held Protara Therapeutics (TARA) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $22.4M of Protara Therapeutics stock for Q1 2018, up 64% quarter-over-quarter.
  • 5 funds opened new Protara Therapeutics positions in Q1 2018 and 5 closed out, a net change of 0 holders.
  • The largest Protara Therapeutics buyer in Q1 2018 was Renaissance Technologies, an estimated $78.7K added.
  • The largest Protara Therapeutics seller in Q1 2018 was Wedbush Securities, an estimated $53K sold.

Based on aggregated 13F filings for Q1 2018.